Alex Herrera
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alex Herrera as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05432635 · Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaCity of Hope Medical Center · recruiting · B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma · principal investigator
- Ph2NCT03057795 · Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaCity of Hope Medical Center · active not recruiting · Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
- Ph2NCT02744612 · Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCity of Hope Medical Center · completed · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2026 · $222,906 awarded in 2026Grant number is on one of their registry trials
- Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer CenterR50CA285409 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $208,103 awarded in 2026Same name and institution; not confirmed by an ID
- Targeted immunotherapy for relapsed/refractory Hodgkin lymphomaP50CA107399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2018 · $336,786 awarded in 2018Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 89 PubMed records, and a shared surname and initials can bring in a namesake. All 89 on PubMed
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol · 20191,947 citationsRCR 70.8
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.J Clin Oncol · 2020655 citationsRCR 30.2
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.Nat Med · 2022266 citationsRCR 16.5
- 260 citationsRCR 8.2
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- 190 citationsRCR 9.9
- Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.Blood Adv · 2022173 citationsRCR 12.0
- PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.Blood · 2019154 citationsRCR 5.3
- 131 citationsRCR 4.9
- The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.J Clin Endocrinol Metab · 2004117 citationsRCR 2.5